200 related articles for article (PubMed ID: 33363038)
21. Case Report: Outcome and Adverse Events of Anti-PD-1 Antibody Plus Chidamide for Relapsed/Refractory Sézary Syndrome: Case Series and A Literature Review.
Chen C; Liu Z; Liu J; Zhang W; Zhou D; Zhang Y
Front Oncol; 2022; 12():842123. PubMed ID: 35387123
[TBL] [Abstract][Full Text] [Related]
22. Successful Treatment of Primary CNS Extranodal NK/T-Cell Lymphoma with Surgery and Chemotherapy Combined with Sintilimab: A Case Report and Literature Review.
Qin L; Li Y; He Y; Zeng R; Pan T; Zuo Y; Xiao L; Zhou H
Onco Targets Ther; 2022; 15():1-11. PubMed ID: 35023929
[TBL] [Abstract][Full Text] [Related]
23. Sintilimab: A Promising Anti-Tumor PD-1 Antibody.
Zhang L; Mai W; Jiang W; Geng Q
Front Oncol; 2020; 10():594558. PubMed ID: 33324564
[TBL] [Abstract][Full Text] [Related]
24. Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
Wang XT; Guo W; Sun M; Han W; Du ZH; Wang XX; Du BB; Bai O
World J Clin Cases; 2020 Jul; 8(14):3122-3129. PubMed ID: 32775395
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment with anti-programmed-death-1 antibody in a relapsed natural killer/T-cell lymphoma patient with multi-line resistance: a case report.
Lai J; Xu P; Jiang X; Zhou S; Liu A
BMC Cancer; 2017 Jul; 17(1):507. PubMed ID: 28754096
[TBL] [Abstract][Full Text] [Related]
26. Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report.
He ZD; Yang HY; Zhou SS; Wang M; Mo QL; Huang FX; Peng ZG
World J Clin Cases; 2022 Feb; 10(4):1341-1348. PubMed ID: 35211568
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
28. Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin.
Yamaguchi M; Suzuki R; Miyazaki K; Amaki J; Takizawa J; Sekiguchi N; Kinoshita S; Tomita N; Wada H; Kobayashi Y; Niitsu N; Ando T; Maeda T; Saito B; Matsuoka H; Sakai R; Kubota N; Masaki Y; Kameoka Y; Asano N; Oguchi M; Katayama N
Ann Hematol; 2019 Jul; 98(7):1647-1655. PubMed ID: 31001658
[TBL] [Abstract][Full Text] [Related]
29. Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma.
Hu B; Oki Y
Front Oncol; 2018; 8():139. PubMed ID: 29761078
[TBL] [Abstract][Full Text] [Related]
30. Recent updates on Sintilimab in solid tumor immunotherapy.
Liu X; Yi Y
Biomark Res; 2020 Dec; 8(1):69. PubMed ID: 33292551
[TBL] [Abstract][Full Text] [Related]
31. Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function.
Zhang H; Lu J; Jiao Y; Chen Q; Li M; Wang Z; Yu Z; Huang X; Yao A; Gao Q; Xie W; Li L; Yao P
Front Oncol; 2018; 8():679. PubMed ID: 30693272
[TBL] [Abstract][Full Text] [Related]
32. Chidamide in the treatment of peripheral T-cell lymphoma.
Chan TS; Tse E; Kwong YL
Onco Targets Ther; 2017; 10():347-352. PubMed ID: 28138258
[TBL] [Abstract][Full Text] [Related]
33. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
[TBL] [Abstract][Full Text] [Related]
34. The landscape of new drugs in extranodal NK/T-cell lymphoma.
Wang L; Li LR; Zhang L; Wang JW
Cancer Treat Rev; 2020 Sep; 89():102065. PubMed ID: 32653806
[TBL] [Abstract][Full Text] [Related]
35. Study of L-Asparaginase, Vincristine, and Dexamethasone Combined With Intensity-modulated Radiation Therapy in Early-Stage Nasal NK/T-Cell Lymphoma.
Hu Y; Chen M; Song Y; Liu X; Gou F; Zhang J; Huang Y
Am J Clin Oncol; 2020 Apr; 43(4):257-262. PubMed ID: 31764026
[TBL] [Abstract][Full Text] [Related]
36. Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature.
Ma S; Dang Q; Yang Y; Liu Y; Sun Y; Sun M
Front Oncol; 2020; 10():526096. PubMed ID: 33194584
[TBL] [Abstract][Full Text] [Related]
37. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial.
Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Zeng S; Zhang Q; Hu J; Zhou H; Xiong Y; Liu P
Lancet Haematol; 2019 Jan; 6(1):e12-e19. PubMed ID: 30612710
[TBL] [Abstract][Full Text] [Related]
38. Anti-PD-1 sintilimab-induced bilateral optic neuropathy in non-small cell lung cancer: A case report and literature review.
Wang J; Xiao X; Dong X; Wu G; Wang X; Zhang R
Front Oncol; 2022; 12():931074. PubMed ID: 36016624
[TBL] [Abstract][Full Text] [Related]
39. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH
J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072
[TBL] [Abstract][Full Text] [Related]
40. Extranodal NK/T Cell Lymphoma with Destruction of the Uvulae: A Case Report.
Jabbari Azad F; Delavarian Z; Hatami M; Rahimi H; Abdolvahed MR
Iran J Otorhinolaryngol; 2017 Mar; 29(91):101-108. PubMed ID: 28393058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
